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Abstract
Background: Nosocomial bloodstream infections (nBSIs) are an important cause of morbidity and mortality and are the
most frequent type of nosocomial infection in pediatric patients.
Methods: We identified the predominant pathogens and antimicrobial susceptibilities of nosocomial bloodstream isolates
in pediatric patients (#16 years of age) in the Brazilian Prospective Surveillance for nBSIs at 16 hospitals from 12 June 2007
to 31 March 2010 (Br SCOPE project).
Results: In our study a total of 2,563 cases of nBSI were reported by hospitals participating in the Br SCOPE project. Among
these, 342 clinically significant episodes of BSI were identified in pediatric patients (#16 years of age). Ninety-six percent of
BSIs were monomicrobial. Gram-negative organisms caused 49.0% of these BSIs, Gram-positive organisms caused 42.6%,
and fungi caused 8.4%. The most common pathogens were Coagulase-negative staphylococci (CoNS) (21.3%), Klebsiella spp.
(15.7%), Staphylococcus aureus (10.6%), and Acinetobacter spp. (9.2%). The crude mortality was 21.6% (74 of 342). Forty-five
percent of nBSIs occurred in a pediatric or neonatal intensive-care unit (ICU). The most frequent underlying conditions were
malignancy, in 95 patients (27.8%). Among the potential factors predisposing patients to BSI, central venous catheters were
the most frequent (66.4%). Methicillin resistance was detected in 37 S. aureus isolates (27.1%). Of the Klebsiella spp. isolates,
43.2% were resistant to ceftriaxone. Of the Acinetobacter spp. and Pseudomonas aeruginosa isolates, 42.9% and 21.4%,
respectively, were resistant to imipenem.
Conclusions: In our multicenter study, we found a high mortality and a large proportion of gram-negative bacilli with
elevated levels of resistance in pediatric patients.
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Introduction
Nosocomial bloodstream infections (nBSIs) are an important
cause of morbidity and mortality and are the most frequent type of
nosocomial infection in pediatric patients [1–4]. The crude
mortality is high, particularly for critically ill patients [2,3,4]. In
the ICU setting children with BSI had crude mortality rates of
52% in an Israeli hospital [2] and 14% in a multicenter study of
US hospitals [1].
In addition to an increase in incidence of nBSI, the proportion
caused by multidrug resistant pathogens is also rising [5]. Despite
advances in antimicrobial treatment, nBSI prolongs hospital stay,
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increases direct patient care costs and directly causes mortality
[6,7].
The rates of antimicrobial resistance among pathogens causing
healthcare associated infection are increasing, mainly among
gram-negative organisms (Pseudomonas aeruginosa, Acinetobacter bau-
mannii and Klebsiella pneumoniae) [8]. Indeed this increase in
antimicrobial resistance demonstrates a need for surveillance
programs to define the species distribution and the resistance
patterns of pathogens that can cause a nBSI in order to help
physicians choose the most appropriate antimicrobial treatment
for hospitalized patients [9].
There are differences in surveillance programs in different parts
of the world with regards to methodologies and populations
studied (e.g., ICU, neutropenic, or haemodialysis patients)
[9,10,11]. There are only a few studies focusing on nBSI in
pediatric patients [1,2]. The purpose of this study was to evaluate
the epidemiological features of nBSI, the species distribution and
the antimicrobial susceptibility of the pathogens in pediatric
patients, using the same methodology of prior studies (US and
Brazilian SCOPE Projects) [9,12].
Methods
The Brazilian Surveillance and Control of Pathogens of
Epidemiologic Importance (Br SCOPE), based at Universidade
Federal de Sao Paulo, Sao Paulo, Brazil, was established to
identify the predominant pathogens and their antimicrobial
susceptibilities of nosocomial bloodstream isolates [12]. The 16
participating hospitals throughout the five different regions in
Brazil (North, Northeast, Middle-East, Southeast, and South),
represent medical institutions of public and private hospitals. The
study was approved by the Institutional Review Board (IRB) at
each participating site and it was submitted to the final approval of
the IRB from Universidade Federal de Sao Paulo. The require-
ments for informed consent was waived by IRB from Universidade
Federal de Sao Paulo in accordance of the Code of Federal
Regulations and of the Privacy Rule.
Study Design
Clinical data and bloodstream isolates were prospectively
collected by local infection-control practitioners using a standard-
ized case-report form and forwarded to the coordinating center
along with each microbiological isolate. We did not perform any
training or data validation as the local infection control
practitioners were experienced in performing surveillance. Patients
admitted between June 12, 2007 and March 31, 2010 to any of the
16 hospitals participating in the Br SOPE Project were eligible if
they were #16 years of age or treated on a pediatric service and
met the criteria for a nosocomial bloodstream infection (BSI). For
some descriptive analyses patients,=1 year old and.5 years old
were compared.
A nosocomial BSI was determined to have occurred if $1
culture of a blood sample obtained $48 hours after admission to
the hospital yielded a pathogenic organism. If the bloodstream
isolate was a potential skin contaminant (e.g., diphtheroids,
Propionibacterium species, Bacillus species, coagulase-negative staph-
ylococci, or micrococci), all of the following criteria were required
for the diagnosis: the presence of an intravascular catheter, the
initiation of targeted antimicrobial therapy, and at least one
clinical finding (temperature .38.0uC or ,36uC, chills, or systolic
blood pressure of ,90 mmHg). BSI episodes that represented
relapses were excluded. We analyzed the data from all eligible
episodes of BSI.
The data that were routinely collected included the patient’s
age, gender, predisposing clinical conditions, species distribution
and antimicrobial susceptibility of causative pathogens and
outcome. Predisposing clinical conditions that were routinely
recorded included neutropenia (defined as an absolute neutrophil
count of ,1000/mL), peritoneal dialysis or hemodialysis, and
presence of intravascular catheters (i.e., central lines, arterial
catheters, or peripheral intravenous catheters). Secondary BSIs
were regarded as those with a clear source of bacteremia other
than a central line. Sources of secondary BSI were identified by
cultures of samples (urine, tracheal secretions, intra-abdominal
samples, etc.) obtained form distant sites that yielded the same
pathogen with an identical resistance pattern. Distant sites were
sites where an infection was diagnosed other than a central line
(pneumonia, urinary tract infection, abdominal infection, etc).
Crude mortality was defined as in-hospital mortality. We also
compared pediatric patients hospitalized at private vs. public
facilities.
Microbiological Methods
Blood cultures were processed at the participating hospitals.
The identification of blood isolates and susceptibility testing were
done with the routine methods in use at the affiliated laboratories.
All affiliated laboratories were Brazilian Society of Clinical
Pathologists-certified, and all microbiological methods used were
consistent with current CLSI recommendations [13]. Data from
all hospitals were used for analysis, and denominators for
individual antimicrobial agents may vary because not all hospitals
test and report all drugs.
At the reference laboratory, Special Microbiology Laboratory
from Universidade Federal de Sa˜o Paulo, samples identified by
manual methods were submitted to re-identification and antimi-
crobial susceptibility test by the Phoenix BD automated system.
MIC determination by E-TEST for oxacillin, and carbapenems
and agar dilution for vancomycin were done to confirm resistant
phenotypes.
Molecular tests were applied to resistant strains as follow:
– For Staphylococcus aureus: mecA detection, SCCmec characteriza-
tion [14,15] and molecular typing by pulsed field electropho-
resis (PFGE);
– Enterococcus spp: vanA and van B detection
– Klebisiella pneumoniae: ESBL detection (blaTEM, blaCTX, blaSHV)
and carbapenemase detection (bla KPC)
Statistical Analysis
The results were expressed as the mean6 SD or as a proportion
of the total number of patients or isolates. For continuous
variables, mean values were compared using two sample t tests for
independent samples. Differences in proportions were compared
using a chi-square test or Fisher’s exact test, as appropriate. All
tests of significance are 2-tailed; a was set at 0.05. All statistical
analyses were done using SPSS software (SPSS).
Results
Study Population and Patient Characteristics
During the study period a total of 2,563 cases of BSI were
reported by hospitals participating in the Br SCOPE project.
Among these, 342 clinically significant episodes of BSI (13.3%)
were identified in pediatric patients (#16 years of age). Patients
had a mean age of 4.765.1 (range, 0 to 16 years), but one-half of
the patients were ,=1 year old (172/342, 50.2%).
Br SCOPE - Bloodstream Infection Surveillance
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At the time of diagnosis of BSI, nearly half of patients were
hospitalized in a pediatric or neonatal intensive care unit (155;
45.3%). Others were in a general pediatric unit (71; 21.0%) or a
pediatric hematology-oncology unit (60; 17.5%). Underlying
conditions were classified as malignancy in 95 patients (27.8%),
followed by respiratory in 54 patients (15.8%), and gastroenter-
ology in 36 patients (10.5%). However, one-fifth of the patients
(n = 65; 19.0%) were hospitalized secondary to conditions
classified as ‘‘other’’. These could not be analyzed further because
of the lack of a classification of conditions seen in pediatric patients
only. Thirty-eight patients (11.1%) were neutropenic at the time of
BSI diagnosis.
Among the potential factors predisposing to BSI, intravascular
devices were the most frequent. Central venous catheters were in
place in 227 patients (66.4%), followed by peripheral iv catheters
in 79 patients (23.1%) and arterial catheters in 9 patients (2.6%). A
total of 61 patients were receiving parenteral nutrition (17.8%),
and in 20 (5.8%) dialysis was needed at the onset of BSI.
Ventilator support was necessary in 130 patients (38.0%). Overall
74 patients died during hospitalization, accounting for a crude
mortality of 21.6%.
Microbiologic Features
During the study period 357 isolates were recovered from 342
episodes of BSI. Of these, a total of 175 (49.0%) were caused by
gram-negative organisms, 152 (42.6%) by gram-positive organ-
isms; and 30 (8.4%) fungi, of which 27 (90.0%) were Candida
species (table 1).
The rank order of the major pathogens (Table 2) shows that
coagulase-negative staphylococci (CoNS), accounted for almost
one-quarter of all nosocomial BSI (21.3%), followed by Klebsiella
species (15.7%), Staphylococcus aureus (10.7%), Acinetobacter species
(9.3%) and Candida species (7.6%). Four percent of all episodes of
BSI (n = 13) were polymicrobial. In these, the most frequently
isolated pathogens (n = 15) were Klebsiella species (33.3%), Candida
species (20.0%), Enterococcus species (13.3%) and Enterobacter species
(13.3%).
When different age groups were compared, the proportion of
CoNS decreased from 50% in patients ,1 year to 19% in patients
.5 years old. The same pattern was seen with S. aureus, Candida
species and Enterococcus species in the same patient populations
decreased from 18%, 13% and 13%, respectively, to 9% for each.
The proportion of Acinetobacter species was higher in patients .5
years old.
In patients with monomicrobial BSI (n = 328), the crude
mortality (Table 2) ranged from 14% (for Pseudomonas aeruginosa)
to 58% (for Candida species). Mortality in patients with polymi-
crobial BSI was 38.5%. Considering facility type, 90.9% (298/328)
had nBSI at a public hospital and 9.1% (30/328) had nBSI at a
private hospital. There was no statistically significant difference
with regard to gender (p = 0.44), age (p = 0.68) and potential risk
factors, such as the central venous catheter (p = 0.62), ventilator
(p = 0.16), or urinary catheter (p = 0.40) between pediatric patients
at a private or a public facility. There was also no statistically
significant difference in crude mortality in pediatric patients at
private (13.8%, 4/29) vs. public facilities (23.5%, 65/277;
p = 0.24).
More pediatric patients acquired nBSI in ICUs in private
facilities (70%, 21/30) than public (48.3%, 144/298), p = 0.024.
Considering the organisms, in private facilities there were 66.7%
(20/30) gram positive nBSIs, 30.0% (9/30) gram negative nBSIs,
and only 3.3% (one case) of fungal nBSI, while in public facilities
there were 49.0% (146/298) gram negative nBSIs, 42.6% gram
positive nBSIs and 8.4% (25/298) fungal nBSI, p = 0.039.
Of the 27 Candida isolates causing nosocomial BSI, Candida
albicans was responsible for 37% of cases of Candida BSI, followed
in rank order by Candida tropicalis (26%) and Candida parapsilosis
(22%). Candida glabrata accounted for only 4% of cases of Candida
BSI.
Antimicrobial Susceptibility
Methicilllin resistance was detected in 37 S. aureus isolates (27%)
and in 76 CoNS isolates (92%). S. aureus strains with reduced
susceptibility to vancomycin were not detected. Reduced suscep-
tibility to teicoplanin was reported in 1 CoNS isolate (3%) (table 3).
Thirty-five CoNS were characterized at species level: Staphylo-
coccus epidermidis (62.8%), followed by Staphylococcus hominis and
Staphylococcus warneri (11.4%), Staphylococcus haemolyticus (8.5%) and
Staphylococcus capitis (5.7%). The susceptibility profile revealed high
resistance rate to oxacilin (80%).
Twenty isolates of Staphylococcus aureus were studied at the
reference laboratory and 5 of them were resistant to oxacilin.
Molecular analysis was performed showing 4 mecA positive isolates.
The characterization of SCCmec revealed 2 SCCmec type III
isolates and one SCCmec type IVa.
For enterococci, vancomycin resistance was found in 19 isolates
(21.0%), 80% of these were E. faecium isolates (N= 5) and none
were E. faecalis strains (N= 8). Eleven Enterococcus spp were studied
at the reference laboratory, 6 E. faecalis and 5 E. faecium. In only 3
E. faecium strains was the vancomycin MIC.256 mg/mL and the
vanA gene was detected in all 3.
Antimicrobial resistance levels for the most common gram-
negative organisms causing nosocomial BSI are shown in table 4.
Relatively high proportions of Klebsiella spp displayed resistance to
ampicillin-sulbactam, piperacillin-tazobactam, ceftazidime, and
Table 1. Epidemiologic and demographic data of pediatric
patients with nBSI.
Patient demographics N (%)
Total pediatric patients 342
Mean Age (±SD), in years 4.7 (65.1)
Gender
Male 176 (51.5%)
Female 166 (48.5%)
ICU setting 172 (50.4%)
Monomicrobial infection 328 (95.9%)
Organisms (N=357)
Gram-negative 175 (49.0%)
Gram-positive 152 (42.6%)
Fungi 30 (8.4%)
Underlying conditions
Malignancy 95 (27.8%)
Respiratory 54 (15.8%)
Gastrointestinal 36 (10.5%)
Other 65 (19.0%)
Potential risk factors
Central venous catheter 227 (66.4%)
Ventilator 130 (38.0%)
Urinary catheter 76 (22.2%)
Crude mortality 74 (21.6%)
doi:10.1371/journal.pone.0068144.t001
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cefepime (60.7%, 40.5%, 38.3%, and 37.7%, respectively).
Resistance to imipenem and meropenem was seen in 2.0% and
1.9% of the isolates.
Eleven out of 39 Klebsiella pneumoniae isolates were phenotypically
characterized as ESBL with the presence of genes blaTEM, blaCTX,
blaSHV in 3 (28.3%), 7 (63.6%) and 5 (45.4%), respectively. One
isolate, resistant to imipenem and meropenem (MIC=8 mg/mL)
was modified Hodge test negative. The molecular analysis by
polymerase chain reaction did not reveal the presence of the
blaKPC gene.
For Acinetobacter spp, cephalosporins, fluoroquinolones, and
carbapenems were not active against almost 40% of the isolates
tested. For Enterobacter species, nearly 40% were resistant to
piperacillin-tazobactam. All Enterobacter species were susceptible to
fluoroquinolones and carbapenems. Of the P. aeruginosa isolates,
almost one-quarter were resistant to cephalosporins, aminoglyco-
sides, fluoroquinolones, piperacillin-tazobactam and carbapenems.
Discussion
National surveillance studies focusing on nBSI are important
tools that can detect specific issues related to antimicrobial
resistance [9,10,11,12]. In addition, BSI surveillance studies are
preferable because rigid and standardized clinical diagnostic
criteria make data more reliable and realistic, avoiding the
problem of confounding colonizing agents not directly related to
clinical disease [9,12]. BSIs are also the most serious and
potentially life-threatening infectious diseases in the pediatric
population and in the majority of cases antimicrobial therapy must
be initiated empirically [1,2,3]. For these reasons accuracy in
predicting the pathogens and the resistance profile is crucial for
successful therapy.
Brazil is a country with more than 150 million inhabitants and a
total surface area larger than 8,500,000 Km2. In addition to its
large geographic size, the country is heterogeneous in socio-
demographic indicators, with wealthier regions concentrated in
the southern part of the country. Although the majority of the
population depends on the public healthcare system, an increasing
Table 2. Rank order of nosocomial bloodstream pathogens in pediatric patients among 16 hospitals throughout Brazil.
Total % of Isolates Crude Mortality*
Organisms No of isolates % of isolates Age ,1 yr Age 1–5 yr Age.5 yr (%)
Coagulase-negative staphylococci 76 21.3 50.0 21.1 19.0 26.3
Klebsiella species 56 15.7 – 19.6 13.8 17.6
Staphylococcus aureus 38 10.6 18.2 11.3 9.5 21.1
Acinetobacter species 33 9.2 – 8.3 13.8 25.0
Candida species 27 7.6 13.7 6.7 8.6 58.3
Enterobacter species 25 7.0 – 10.3 2.6 21.7
Enterococcus species 21 5.9 13.7 3.4 9.5 30.8
Pseudomonas aeruginosa 14 3.9 – 5.4 2.6 14.3
Escherichia coli 14 3.9 – 4.4 4.3 21.4
Streptococcus species 12 3.4 – 2.9 5.2 16.7
Serratia species 6 1.7 – 2.0 1.7 50.0
*Crude mortality of patients with monomicrobial BSI.
doi:10.1371/journal.pone.0068144.t002
Table 3. Rates of antimicrobial resistance among gram-positive organisms most frequently isolated from children with nosocomial
bloodstream infection.
Staphylococcus aureus CoNS Enterococcus spp
Antimicrobial drug No. of isolates % resistant No. of isolates % resistant No. of isolates % resistant
Ampicillin ND – ND – 19 36.8
Methicillin 37 27.1 76 92.1 ND –
Cefazolin 25 16.0 28 92.9 ND –
Vancomycin 37 0 76 0 19 21.0
Teicoplanin 7 0 34 2.9 7 0
Linezolid 26 0 70 0 16 0
Ciprofloxacin 24 16.7 41 56.1 5 0
Clindamycin 35 22.9 72 73.6 ND –
Gentamicin 36 19.4 73 60.3 17 11.8
CoNS = Coagulase-negative staphylococci; ND = Not done.
doi:10.1371/journal.pone.0068144.t003
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fraction is being managed by private facilities. Heterogeneity is
also reflected in healthcare practices at the level of nosocomial
infection management. As a result, different patterns of antimi-
crobial resistance and antimicrobial use may emerge within the
country [12]. Also, due to its intrinsic characteristics, etiologic
agents and their respective antimicrobial susceptibilities may differ
from those of other countries [9,10].
In this study, we analyzed 342 nBSI episodes in pediatric
patients that were prospectively collected at 16 Brazilian medical
centers between 2007 to 2010. This is the largest study done in the
pediatric population in this country and it is important because
epidemiological and resistance data of the adult population are
frequently extrapolated to children. The knowledge of Brazilian
data is of paramount importance for determining regional and
national prevention and treatment strategies for nosocomial
infections. Different from other previous nationwide network
surveillance studies, the Br SCOPE Study [12], similar to the US
SCOPE Study [9], is representative of the whole country,
obtaining data from its 5 different geographical regions. Also,
standardized criteria for BSI were applied, conferring reliability
for comparison with other studies.
The crude mortality was 21% in this pediatric cohort, half of
that observed in the adult population evaluated by the Br SCOPE
[12], but higher than that reported by the US SCOPE Project
(14%) [9]. However, US SCOPE (9) analyzed more ICU patients
and fewer oncologic patients. We suspect that the higher mortality
rate observed in our study was due to higher resistance levels in the
gram negative bacilli. There was no difference in mortality rates
between pediatric patients with nBSI in public or private facilities.
When we analyzed by pathogen, higher mortality was observed
in Candida species (58.3%). This has been reported in other studies
and may be due to the severity of the illness and the greater time to
positive blood cultures, which accounts for a delay in the start of
therapy. Another important finding of this study is the high
mortality rate observed in patients with polymicrobial bacteremia
(38%), possibly related to the difficulties in therapeutic manage-
ment.
Like other studies of nBSI and/or healthcare related infections
in Latin America [10,12], we observed a higher prevalence of
gram-negative bacilli over gram-positive cocci (49% vs 42.6%,
respectively), whereas the US SCOPE found that only 24% of
infections were due to gram-negative bacilli [9]. Of note, in the
adult Br SCOPE population, the proportion of infections due to
gram- negative bacilli was even higher (58.5%) [12]. This high
prevalence of gram-negative bacilli in Brazil has a practical
importance, especially when dealing with empiric treatment of
suspected BSI infection since our data suggest that an antimicro-
bial agent directed against gram-negative pathogens is mandatory.
We observed a higher proportion of gram negative nBSI in public
hospitals (49%) than in private hospitals (30%) in our pediatric
population.
It must be emphasized that in our study, in children younger
than one year old, half of the nBSI were caused by coagulase
negative staphylococci (CoNS) with an associated elevated crude
mortality (26.3%), unlike that observed in other studies [16,17]
and this fact may be related to the high severity of infections in this
age group. In the US SCOPE [9] it also was observed that many
infections were caused by these agents in children less than one
year old, but with only 10% mortality, which is what is expected
for these agents and has been reported by other authors [16,17].
High levels of resistance were observed in Klebsiella pneumoniae:
40% to cephalosporins (3rd and 4th generations) and piperacillin/
tazobactan, when compared to data from US SCOPE [9], where
only 10% were resistant to ceftazidime and 30% to piperacillin.
However, a high level of susceptibility to carbapenems was
observed in both studies. Although high, the resistance profile to
cephalosporins was smaller than that observed in the Br SCOPE
[12]. In this study, no carbapenamase-producing organisms were
found and the majority of ESBLs were due to gen blaCTX.
Regarding Pseudomonas aeruginosa, US SCOPE [9] found a low
level of resistance (,10%) to the majority of antibiotic agents. In
our study, the resistance was greater than 20% for all antibiotics.
The worst resistance was observed with Acinetobacter baumanni:
more than 55% were resistant to piperacillin/tazobactan and
cephalosporins (3rd and 4th generations), 40% were resistant to
carbapenems and ciprofloxacin. However, a greater level of
resistance was observed in the adult Br SCOPE population
(approximately 60% to carbapenems and 70% to cephalosporins
and ciprofloxacin) [12]. These data confirm the high and
worrisome level of resistance among gram-negative bacilli in
Table 4. Rates of antimicrobial resistance among gram-negative organisms most frequently isolated from children with
nosocomial bloodstream infection.
Klebsiella pneumoniae
Acinetobacter baumannii
Enterobacter species Pseudomonas aeruginosa
Antimicrobial drug No. of isolates % resistant No. of isolates % resistant
No. of
isolates % resistant
No. of
isolates % resistant
Amp-Sul 28 60.7 24 33.3 ND – ND –
Pip-Tazo 37 40.5 18 55.6 22 36.4 12 25.0
Cefazolin ND – ND – ND – ND –
Ceftriaxone 44 43.2 ND – ND – ND –
Ceftazidime 47 38.3 27 55.6 24 29.2 13 38.5
Cefepime 53 37.7 28 50.0 26 7.7 12 25.0
Imipenem 51 2.0 28 42.9 26 0 14 21.4
Meropenem 52 1.9 29 37.9 24 0 13 23.1
Ciprofloxacin 52 15.4 29 37.9 25 0 14 21.4
Gentamicin 47 32.7 27 25.9 25 8.0 12 25.0
ND = Not done; Amp-Sul = ampicillin-sulbactam; Pip-Tazo = Piperacillin-tazobactam.
doi:10.1371/journal.pone.0068144.t004
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Brazil, and the high prevalence of these agents may have a serious
impact on antibiotic management, creating a vicious cycle of
heavy use and resistance development.
Antibiotic resistance among the gram-negative bacteria is
worrisome, especially regarding P. aeruginosa and Acinetobacter
baumanii. Rates as high as 40% resistance to carbapenems for
Acinetobacter and 23% for P. aeruginosa are among the highest in the
world’s literature in the pediatric population and have several
implications for clinical practice [15,18]. Since resistance to
carbapenems usually is associated with multi-drug resistance [19],
very few options remain viable. In some instances, polymyxins
remain the last alternative [20] and these drugs already widely
used in Brazil [21] could be considered in empiric therapy for the
subgroup of patients prone to develop BSI due to these agents.
Fungal nBSI has become more frequent. We found a prevalence
of 8.4%, a slightly lower than that found in US SCOPE (9.3%) [9]
and higher than that observed in adult Br SCOPE (6.1%) [12].
Possibly, it is due to a greater concentration of oncologic patients.
Moreover, 11% of these patients were neutropenic at the time of
BSI diagnosis.
In this study, species of Candida represented 7.6% of nBSI, the
majority caused by non-albicans species (63%), mainly C. tropicalis
and C. parapsilosis, similar to data from adult patients [12].
In conclusion, our study describes the pattern of nBSI in
Brazilian children. We found a higher mortality in comparison to
data from the US [9] and a larger proportion of gram-negative
bacilli with elevated levels of resistance. This finding may aid
Brazilian physicians in the empirical treatment of BSI in pediatric
patients.
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